A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells

Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(...

Descripción completa

Detalles Bibliográficos
Autores principales: Natarajan, Gayathri, Oghumu, Steve, Terrazas, Cesar, Varikuti, Sanjay, Byrd, John C., Satoskar, Abhay R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938315/
https://www.ncbi.nlm.nih.gov/pubmed/27471620
http://dx.doi.org/10.1080/2162402X.2016.1151592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938315/
https://www.ncbi.nlm.nih.gov/pubmed/27471620
http://dx.doi.org/10.1080/2162402X.2016.1151592

Ejemplares similares